Vector Biolabs, a custom design and manufacturing service provider of AAV and adenoviral vectors, has announced the completion of a facility expansion to meet growing demand.
The purpose of the expansion was twofold – it doubles our capacity, allowing us to expand our custom AAV and Adenovirus production services to a broader audience in gene delivery, gene editing, and cell therapy applications, and it adds cleanroom space and analytical instrumentation to support our customers’ quality needs as they progress from During preclinical studies and towards presenting IND. “
Ken Guo, Co-Founder, Vector Biolabs.
The new facility includes a manufacturing suite of cleanrooms, quality control laboratories, warehousing and office space. The additional capacity will allow Vector to maintain its current rapid turnaround time as demand increases in the field, as well as add new product properties and quality control services to its offering. XD Shao, co-founder, noted that the team at Vector is growing along with the facility. “Vector has served as a reliable scientific and development collaborator for our clients’ research initiatives since 2004. We provide project-specific technical expertise and insight to hundreds of clients across pharma, biotech, and academia based on our decades of experience in the viral vector field. As we add capabilities, so do we. We are keen to maintain the collaborative service that has made us the most cited company in gene delivery.”